Published by Iain Gilbert on 20th April 2026
(Sharecast News) - Drugmaker GSK said on Monday that its relapsed/refractory multiple myeloma treatment Blenrep had received approval from China's National Medical Products Administration, making it the only anti-BCMA cleared for use in the country.
URL: http://www.digitallook.com/dl/news/story/35863595/...